NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Time Cap Pharma Labs Pvt Ltd NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Time Cap Pharma Labs Pvt Ltd NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Paper notice publication for 37th AGM Notice, remote e voting and book closure dates
Natco Pharma aims to diversify product portfolio in domestic market
New Delhi, Sep 21 Natco Pharma plans to diversify its product portfolio in the domestic market as it aims to make up for a drop in business of some..
Buy Natco Pharma: target of Rs 954: ICICI Securities
ICICI Securities is bullish on Natco Pharma recommended buy rating on the stock with a target price of Rs 954 in its research report dated September 18, 2020. NATCO PHARMA LTD. - 524816 - 37Th Annual General Meeting To Be Held On 15Th October, 2020
37th Annual General Meeting to be held on 15th October, 2020 NATCO PHARMA LTD. - 524816 - Book Closure For The Purpose Of 37Th Annual General Meeting To Be Held On 15Th October, 2020
Book Closure for the purpose of 37th Annual General Meeting to be held on 15th October, 2020 NATCO PHARMA LTD. - 524816 - Reg. 34 (1) Annual Report
Notice of 37th Annual General Meeting for the financial year 2019-20 Natco Pharma to make Time Cap Overseas a wholly-owned arm
This will be all-cash transaction NATCO PHARMA LTD. - 524816 - Outcome Of The Board Meeting Held On 10Th September, 2020
outcome of the Board Meeting held on 10th September, 2020